MammoCommunicate Mini Moments

Can a facility replace the FDA's density wording with its own wording, or with a list of key points?

What it is

No. The FDA said it is not providing alternative density reporting language and is not changing the notification from a required paragraph to a list of key points. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

The FDA gave two reasons: it wants patients to receive a consistent baseline of information about their breast density, and it wants the notification to be easy to verify during the MQSA inspection. The FDA said States and facilities may give patients additional information where it does not conflict with MQSA and its regulations. For States that require four density categories, the FDA said facilities may also give that information to patients, but it is distinct from the notification paragraph that the MQSA rule requires.

Why it matters

The required paragraph is checked against the exact text at inspection, so it needs to appear as written.

What it means to the patient or the client

For the client: keep the FDA paragraph word for word in the lay summary, and place any State-required four category information in a separate, labeled part of the letter.

Can a facility use different lay summary versions for patients who get results at the visit and by mail?

What it is

Yes, but the FDA does not require different versions, and any version has to include the required density language in 21 CFR 900.12(c)(2). The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

A commenter asked that facilities be required to have separate lay summaries for those given at the time of service and those that are mailed. The FDA said it is not necessary, and that the rule does not prohibit a facility from adopting that practice. The same reasoning applies to additional information: the required wording is a baseline, and facilities may add to it.

Why it matters

Facilities may tailor delivery, but the required statements cannot be dropped from any version.

What it means to the patient or the client

For the client: if you use more than one lay summary template, check each one against the required text, and test the process whenever a template or the delivery method changes.

Can the density statement go on a separate attachment, or be edited for a single breast?

What it is

The FDA's Small Entity Compliance Guide says there is no specific format for the lay summary, but the required elements must all appear within the same lay summary. Those include the patient's name, the facility's name, address, and telephone number, and one of the two FDA density notification statements (21 CFR 900.12(c)(2)).

How it works

For a mammography report, one of the density assessments in 21 CFR 900.12(c)(1)(vi) must be included. Asked whether the wording could change from the breasts are almost entirely fatty to the breast is almost entirely fatty for a unilateral exam, the FDA's answer repeated that the required language is meant to give patients nationwide consistent baseline density information, and did not approve a change. The guide also says that software cleared by the FDA may aid density assessment, but the assessment is part of the interpretation and must be made by a qualified interpreting physician.

Why it matters

A density statement that is not in the same lay summary, or whose wording is changed, may not meet the requirement.

What it means to the patient or the client

For the client: keep the density paragraph inside the lay summary itself, and use the FDA wording as written even for single breast exams, then ask your certifying agency if a case seems to need an exception.

Do facilities in States with their own density laws still have to use the federal density wording?

What it is

Yes. The FDA said all facilities providing mammography services must comply with its breast density reporting requirements, regardless of whether there are applicable State requirements. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

Under 21 CFR 900.12(c)(1)(vi), (c)(2)(iii), and (c)(2)(iv), facilities must provide the specified breast density information in mammography reports to healthcare providers and in lay summaries to patients. The regulations do not include exceptions for facilities in States with breast density reporting requirements. The FDA declined to let State wording be used alone, saying a consistent national baseline ensures that density reporting occurs in every State and that patients and providers receive accurate, complete, and understandable information.

Why it matters

The federal statements are the minimum that goes to every patient, even where a State law also applies.

What it means to the patient or the client

For patients: you should receive the federal density statement whatever State you live in. For the client: include the federal statements in every lay summary, and add any State wording separately.

Do the density assessment and the density notification apply to every mammogram, whatever the exam type, the patient's sex, or the number of breasts imaged?

What it is

Yes. The FDA's Small Entity Compliance Guide says that since September 10, 2024 the breast density assessment must appear on every mammography report and the density notification statement on every lay summary, with no distinction by exam type, patient sex, or whether the exam is of one breast or both.

How it works

For exam type, the regulations require a report and a lay summary for each mammographic examination performed under the facility's certificate, and they do not separate screening from diagnostic mammograms (21 CFR 900.2(aa) and 900.12(c)). For patient sex, the guide points out that a patient is defined as any individual who undergoes a mammography evaluation in a facility, so the requirements apply to patients of any sex. For unilateral exams, it says the amended regulations make no difference between unilateral and bilateral mammograms (21 CFR 900.12(c)(1)(vi) and (c)(2)(iii) and (iv)).

Why it matters

No exam is exempt, so a template or process that skips diagnostic, unilateral, or male patient exams will miss a requirement.

What it means to the patient or the client

For the client: check that your report and lay summary templates fire for every exam type, for every patient regardless of recorded sex, and for single breast exams.

Does the breast density notification require a recommendation for a risk assessment?

What it is

No. The FDA declined to require that the report to the healthcare provider include a recommendation that the provider perform a risk assessment. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

The FDA said the reporting requirements are intended to promote clear communication about the results of the mammogram, not to prescribe other aspects of patient care, and that it generally defers to healthcare providers to decide when a risk assessment is appropriate. Both patient statements say, in part, to talk to your healthcare provider about breast density, risks for breast cancer, and your individual situation (21 CFR 900.12(c)(2)(iii) and (iv)). The FDA said it believes this conversation is the opportunity for the provider to assess the patient's individual risk factors.

Why it matters

The notification is a baseline communication standard. It points the patient to her provider and leaves the risk decision there.

What it means to the patient or the client

For patients: your lay summary tells you to talk with your healthcare provider about density and risk. For the client: if you want to offer risk assessment, that is a service decision, not a rule requirement.

Does the dense breast statement tell patients they need more imaging?

What it is

No. The dense breast statement says that in some people with dense tissue, other imaging tests in addition to a mammogram may help find cancers, which the FDA revised from an earlier proposal that said some patients may need additional imaging. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

The FDA said the language is not intended to require additional imaging for patients with dense breasts, and that it provides a baseline for discussion between a patient and their healthcare provider. It also said the statement is supported by many studies showing higher cancer detection with supplemental imaging in dense breasts. In response to a comment, the FDA added to both statements the sentence that dense tissue makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer, and it kept the word may in the imaging sentence.

Why it matters

The wording informs patients without setting a clinical pathway, which stays with the patient and provider.

What it means to the patient or the client

For patients: the statement is a prompt to talk with your healthcare provider about your own situation, not an instruction to get more tests. For the client: staff should not describe the statement as a recommendation for additional imaging.

Does the density statement have to appear in a particular place in the lay summary?

What it is

No. The FDA declined to require that the breast density notification be placed at the top of the letter or in any specific position relative to the other results information. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

Commenters asked for the density information to come first instead of following the result. The FDA said it is unduly restrictive and potentially confusing to fix a location, given the range of mammogram results and recommendations a facility may need to communicate. It also noted that the lay summary is not required to include an assessment category or statement. The required density language in 21 CFR 900.12(c)(2)(iii) and (iv) must still be included in every version of the lay summary.

Why it matters

The facility chooses the layout, but the required statement has to be present and readable.

What it means to the patient or the client

For the client: place the density statement where patients will see it, and check every lay summary template, including mailed and delivered versions, for the required text.

Does the federal density notification override State breast density laws?

What it is

Not categorically. The FDA said the MQSA preserves State laws that are at least as stringent as the federal requirements (42 U.S.C. 263b(m)). The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

The FDA said its reporting requirements do not preempt State requirements that are at least as stringent. The statute does not resolve which less stringent State requirements may be preempted, and the FDA has not undertaken a 50-state analysis. It gave two examples of State laws that could be preempted: one that prohibited giving a density notification to patients with non-dense breasts, because a facility could not comply with both laws, and one requiring a statement that contradicts a key message, such as that dense tissue makes it harder to find breast cancer on a mammogram.

Why it matters

State laws that add to the federal requirements stay in force. A State law that conflicts could be set aside.

What it means to the patient or the client

For the client: do not drop State-required wording because the federal rule exists. Compare each State requirement with the federal statements, and ask your State agency or counsel about any conflict.

Does the lay summary call dense breasts normal or abnormal, or say that dense breasts are common?

What it is

No to all three. The FDA agreed it is not necessary to describe dense tissue as normal or abnormal, and the final rule does not use the words normal or abnormal in either density statement. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

Commenters disagreed with each other, with some asking for caution about the word normal and others asking the lay summary to say dense breasts are not abnormal. The FDA also agreed that dense tissue is common but declined to add that most women with dense breasts are not at elevated risk, saying studies show women with dense breast tissue do have an elevated risk of developing breast cancer. The final wording states instead that dense tissue makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer.

Why it matters

The statement focuses on whether tissue is dense or not dense and what that means for finding cancer, not on labeling it normal.

What it means to the patient or the client

For patients: dense breast tissue is common, and the letter tells you your tissue is dense so you can talk with your healthcare provider about your own situation. For the client: staff should not describe dense tissue as normal or abnormal when answering patient questions.

Does the lay summary tell patients to keep getting routine screening mammograms or that density can change?

What it is

No. The FDA declined to add a statement telling patients to continue routine screening, and declined to add a statement that breast density and other risk factors can change. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

The FDA said screening methods and time intervals are part of a larger discussion that belongs between a patient and the patient's healthcare provider. It said adding a statement that density can change may be confusing and may detract from the information about the patient's current density assessment. The required language already recommends that the patient talk with their healthcare provider. The FDA noted that facilities may provide additional information beyond the required wording where it does not conflict with MQSA and its regulations.

Why it matters

The required text is limited to the current density result and the prompt to talk to a provider.

What it means to the patient or the client

For patients: ask your healthcare provider when to have your next mammogram. For the client: if you want screening reminder language in letters, add it as separate text that does not replace or alter the required statement.

How can a facility tell whether a State density requirement is more stringent than the federal one?

What it is

The FDA has not decided that for facilities. It said it has not conducted a State-by-State analysis of whether current State laws are more or less stringent than its breast density reporting requirements. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

Because all facilities must comply with the federal requirements regardless of State law, the question matters mainly where a State law and the federal rule differ. The FDA pointed to a definition of more stringent that it uses for device preemption under section 521 of the Federal Food, Drug, and Cosmetic Act: a requirement of greater restrictiveness, or one expected to afford those exposed to a risk of injury from a device a higher degree of protection (21 CFR 808.3(c)). That definition is from a different context and is not a test for State density laws.

Why it matters

There is no federal list or ruling on which State density laws are more stringent, so the facility has to make the comparison itself.

What it means to the patient or the client

For the client: have counsel or your State agency compare each State density requirement with the federal statements, and keep a record of the conclusion and the date.

May a facility add the BI-RADS density letter, or the patient's specific density category, to its reports and lay summaries?

What it is

Facilities may add them, but not in place of the required wording. The FDA's Small Entity Compliance Guide says the ACR BI-RADS density letter categories are not required in the mammography report, and that a letter category alone does not satisfy the requirement.

How it works

One of the four specific federal density assessments must appear in the report to the referring provider. For the lay summary, one of the two federal notification statements must be included. The guide says the regulations do not prohibit additional information, such as telling a patient that her tissue is extremely dense, but that any additional information should generally be separate and distinct from the required federal statement. That keeps patients receiving the same baseline density information in easily understandable language. The guide says this includes information required by a State density law.

Why it matters

Extra detail is allowed, but it must not replace or reword the federal statement.

What it means to the patient or the client

For the client: put any added density detail, State required wording, or letter category in a separate, labeled part of the letter, and leave the federal statement unchanged.

What does the NAPBC screening standard require about breast density and supplemental screening?

What it is

The 2024 standards of the National Accreditation Program for Breast Centers (NAPBC), Standard 5.1, require an accredited program to use nationally recognized screening guidelines and to adopt a protocol for notifying and educating patients with increased breast density.

How it works

The protocol must also cover guidelines for supplemental screening for those patients and the appropriate use of available screening techniques, such as tomosynthesis, breast ultrasound, MRI, molecular breast imaging, and contrast-enhanced mammography. Patients who receive a screening mammogram must also be given evidence-based risk reduction strategies, either discussed with them or provided in writing or electronically, and patients identified as high risk must be referred to appropriate providers (Standard 5.4). The program's breast leadership committee must review these items once each accreditation cycle and document it in its minutes. The standards say programs must follow local, State, and federal privacy requirements, which vary by State.

Why it matters

Accredited breast centers must have a written density process that goes beyond the federal lay summary.

What it means to the patient or the client

For the client: if your center is NAPBC accredited or plans to be, keep the density protocol, the supplemental screening guidelines, and the committee minutes together so a reviewer can see all three. MQSA's lay summary statement is the floor, not the whole process.

What if a patient's density category changes from one mammogram to the next?

What it is

The FDA acknowledged that some patients may see variability in density assessment because of differences between readers and within the same reader, and said it does not outweigh the importance of communicating density. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

The FDA noted that advances in technology, such as density classification software devices, may help reduce variability. It disagreed that patients will lose confidence in mammography when an assessment changes. It said a patient with concerns about any part of the mammogram, including the density assessment, can contact the referring provider or the mammography facility, and that the rule requires facilities to provide mammogram studies and reports to patients on request under 21 CFR 900.12(c)(4).

Why it matters

A changed category is a recognized possibility, and patients have a route to ask about it.

What it means to the patient or the client

For patients: if your density category differs from last time, ask your healthcare provider or the facility about it. For the client: have staff ready to route these questions to the interpreting physician, and honor requests for reports and images.

What reading level does the FDA's density wording for patients target?

What it is

The FDA said both lay summary density statements are below the eighth grade reading level on the Flesch-Kincaid scale. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

The FDA said the wording is the result of discussion between clinicians, patients, and the FDA, and that it represents a balance between patient understandability and accuracy. In response to comments that existing State notices were hard to understand, the FDA said it cannot comment on State wording and recommends that patients speak with their healthcare provider about any language they do not understand.

Why it matters

The federal wording was written to be readable, so facilities should not need to rewrite it.

What it means to the patient or the client

For the client: use the FDA wording as written. Any added text is your own, and it is worth checking that the added text is no harder to read than the required statements.

Why did the FDA require density notification when some commenters questioned its benefit?

What it is

The FDA said that informing patients about their breast density, in a consistent way, is a benefit in itself and supports informed, shared decisions between patients and their healthcare providers. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

Commenters argued the requirement was not backed by evidence, would cause worry without specific actions, or risked overdiagnosis and overtreatment. The FDA disagreed that the requirement should be withdrawn. It said the rule does not specify follow-up imaging, only that patients and providers be notified, and that the statement recommends the patient talk with their healthcare provider. It said the wording is intended as a baseline that patients and providers can use to guide care, and that including a wider range of information that lacks broad scientific consensus, or that may change, could increase patient confusion and reduce the notice's effectiveness. The FDA also pointed out that most States already had density notification requirements that vary, which supported a consistent national baseline.

Why it matters

The rule rests on informing patients, not on mandating any particular test.

What it means to the patient or the client

For patients: the notice is meant to start a conversation with your healthcare provider. For the client: describe the notification as information and a prompt to talk with a provider, not as a diagnosis or a recommendation.

Why did the FDA require uniform density wording instead of letting each State's language be used?

What it is

The FDA explained that it wanted a consistent national baseline of density information, drafted by FDA subject matter experts in easily understandable language. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

It said that not all States have a density reporting requirement, so without a federal rule patients in those States would generally receive no density information. It also said that even where States have requirements, a single consistent set of FDA-required information is valuable, and that the FDA lacks the resources to monitor all State laws. The final rule simplified the statements to two versions for patients, each ending with the recommendation to talk to a healthcare provider, and the FDA described the lay summary text as four to five lines. It said facilities would not need to write their own language, only add the FDA text.

Why it matters

Uniform wording reduces gaps and mistakes and is simple for facilities to implement.

What it means to the patient or the client

For patients: you receive the same core information about density wherever you are screened. For the client: use the federal text as written and add any State or local wording as a separate, clearly labeled section.

Why does a patient with non-dense breasts still get a density notification and a suggestion to talk to a provider?

What it is

The FDA requires a density statement in the lay summary for patients in every density category, including a not dense statement at 21 CFR 900.12(c)(2)(iii). Both statements recommend talking with a healthcare provider. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

Commenters asked that notification go only to patients with dense tissue, that the non-dense wording be minimized, and that non-dense patients not be told to talk to a provider. The FDA disagreed on each point. It said a primary goal of the provision is to give all patients and their healthcare providers information to help guide each patient's care, and that a conversation about breast density is appropriate for patients in all categories. The FDA also removed the introductory phrase Some patients from the wording, but disagreed that basic density information would alarm patients with non-dense tissue.

Why it matters

Every patient with a mammogram receives a density statement, so a facility cannot send it only when tissue is dense.

What it means to the patient or the client

For patients: you receive a density statement whether your tissue is dense or not dense. For the client: check that the lay summary template selects the correct statement from the density category in the report, and that no letter goes out without one.

Why does the density wording no longer mention more glands than fat?

What it is

The FDA deleted the phrase more glands than fat in the breasts from the proposed patient density wording, and the final rule also avoids the term glandular tissue in the lay summary and in the report categories. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

Commenters said the phrase was inaccurate because fat and glandular tissue vary by region, because fibrous tissue is different from glandular tissue and often accounts for much of the density on a mammogram, and because other factors such as compression also affect how density appears. The FDA acknowledged the fibrous stroma in the breast and agreed that many anatomic and technical factors contribute to mammographic density, so it agreed with the deletion. The report to the healthcare provider still uses the phrase scattered areas of fibroglandular density because it conforms to current clinical practice.

Why it matters

The final wording avoids a claim that experts said was not accurate for every patient.

What it means to the patient or the client

For the client: if your templates date from before the final rule or from the proposed language, compare them against the current 21 CFR 900.12(c)(2)(iii) and (iv) text and remove any older phrases.

Why does the lay summary use only two density statements instead of four?

What it is

The FDA concluded that two statements, one for dense and one for not dense breast tissue, give patients a clear message, and that four unique statements would add confusion and burden. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

Commenters asked for four patient statements or for more detailed explanation of what dense and not dense mean. The FDA said the purpose of the letter is not to serve as a complete resource on breast density, and that longer wording might detract from the notice, including by discouraging patients from reading it. In the final rule the FDA also replaced the proposed wording of high density and low density with dense and not dense, which it concluded is clearer to patients.

Why it matters

A short two-way message is easier for patients to read and for facilities to apply.

What it means to the patient or the client

For patients: the letter tells you whether your tissue is dense or not dense, and your healthcare provider can explain more. For the client: build the lay summary template with two required versions and choose between them based on the density category in the report.

Why does the report to the healthcare provider use four density categories, including almost entirely fatty?

What it is

The four report categories in 21 CFR 900.12(c)(1)(vi)(A) through (D) correspond to the density categories in the 5th edition of BI-RADS, and the FDA kept the wording because it is already in widespread use. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

A commenter asked the FDA to replace the almost entirely fatty category with a low density sentence because of negative connotations. The FDA declined, saying it would be unclear whether low density referred to the first category or to scattered areas of fibroglandular density. The FDA noted that the four-category statement goes only in the report to the healthcare provider, not in the lay summary, so patients with a referring provider will not receive it. Self-referred patients receive both the report and the lay summary, which the FDA said should help reduce unintended negative reactions. The FDA also declined to add the BI-RADS categories to the regulations by name.

Why it matters

Providers get the familiar four-category language, and patients get the simpler two-statement lay summary.

What it means to the patient or the client

For the client: keep the four category wording in provider reports exactly as the rule gives it, and make sure self-referred patients also receive the lay summary that explains density in plain language.

Why does the required lay summary leave out visual aids, medical term definitions, and patient education?

What it is

The FDA treats the lay summary language as a baseline, not a full education resource. It declined to require visual aids, explanations of medical terms, added information about mammography limits, or a plan of management in the lay summary. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

The FDA said the required statements already avoid medical terminology, and that the dense-tissue statement already addresses a limit of mammography by saying that dense tissue makes cancer harder to find on a mammogram. It said cartoons or visual aids could distract from the primary message about the patient's density, and that the lay summary is written by the facility while the plan of clinical management is developed by the patient and the healthcare provider. The FDA said facilities may add information or explanation they think their patients need, and that patients with limited literacy may need help interpreting the lay summary.

Why it matters

The required text stays short so patients read it, and any added help is the facility's choice.

What it means to the patient or the client

For patients: ask your healthcare provider about anything in the letter you do not understand. For the client: consider a separate, clearly labeled education sheet or reading support for patients who need it, without changing the required wording.

What are five books, podcasts, or newsletters a breast imaging administrator should follow to become smarter about healthcare operations outside of radiology?

What it is

Mammologix does not recommend a fixed list of five. Healthcare operations has become too diverse for one list to fit everyone, so the first step is choosing a lane [1].

How it works

Mammologix recommends that an administrator first decide on the area to grow in, such as auditing, operations, patient management, analytics, or the use of AI. Next, join professional communities on LinkedIn, find the thought leaders active in that lane, and follow what they are discussing. Then add sites that cover the full breadth of radiology administration, such as AuntMinnie.com, and look beyond radiology to healthcare as a whole. The Mammologix news feed at mammologix.com is another way to stay current. A feed reader such as Feedly can pull the chosen sources into one place [1].

Why it matters

A fixed list goes stale and may not match the administrator's actual focus. Knowing where to look keeps the information current.

Administration attestation to standard operating policy and procedure

Is the newsletter public or client-only?

What it is

The Mammologix newsletter is public. It is not limited to clients [1].

How it works

Mammologix tries to be as transparent as possible. It makes as many of its policies and procedures as possible open to the public for review. It also publishes its terms of service, its pricing, and its newsletter. Mammologix keeps a blog on LinkedIn and offers thousands of resources for free, with none of them behind a paywall. Anyone can also call Mammologix with a question, whether or not they are a client [1].

Why it matters

A facility can judge how Mammologix works, and what it costs, before any sales conversation.

Administration attestation to standard operating policy and procedure

What is the difference between Self-Service letters and Premier full-service for a mid-size outpatient center?

What it is

With Self-Service, Mammologix prepares the letters and the facility prints and mails them. With Premier full-service, Mammologix handles the whole process, and the facility only reviews [1].

How it works

In Self-Service, Mammologix delivers prepped and formatted letters on a consistent daily schedule for patients whose breast imaging is ready for communication. The facility prints them and gets them into the mail. In Premier full-service, Mammologix also prints and mails the letters. Printing runs through an in-house boutique print house with dedicated equipment for small runs. Mailing runs through Mammologix's partnership with the US Postal Service and Pitney Bowes, which allows delivery to be monitored. The client can review each step or let the process run on its own under client oversight [1].

Why it matters

Self-Service lifts the preparation work. Premier lifts printing and mailing too, and the work continues every day whether or not the facility is short-staffed or busy. For many facilities the hard part is getting letters out the door and into the mail stream.

Administration attestation to standard operating policy and procedure

Are communication logs included?

What it is

Yes. Mammologix produces a communication log with each dispatch run, and it also keeps an individual log for each patient [1].

How it works

Mammologix works to shorten the time between a result being transmitted to it, processed, and the patient's lay letter being dispatched. To do that, it uses a dispatching model of three runs a day, though the schedule can depend on what the client wants. Each dispatch carries its own communication log. Separately, an individual log is available for each patient, showing each communication that patient has had [1].

Why it matters

The dispatch logs show what went out in each run, and the patient log shows one patient's full communication history. Together they give the client a record to refer to when a letter is questioned or a patient calls.

Administration attestation to standard operating policy and procedure

How can we tell whether patients really understand the letters we send them?

What it is

No single score answers this question. Mammologix gives clients three kinds of tools: readability and understandability tools, reporting tools that show what patients do after the letter, and A/B testing. They are part of the program and carry no separate charge [3].

How it works

Readability tools include the Flesch-Kincaid grade level and PEMAT, the Patient Education Materials Assessment Tool, which rates understandability and actionability [2]. Mammologix auditing and reporting tools measure outcomes, such as whether patients return and which patients have follow-up recommended. For A/B testing, a client can send one set of letters to one group of patients and a second set to another group. The client's own teams, such as marketing, can then follow up, and the client can compare the results with internal satisfaction measures such as Press Ganey. Mammologix works with each client on any of these.

Why it matters

A readability score shows how a letter reads, not whether the patient acted on it. One institution that rewrote its recall letter to about a sixth-grade reading level saw 60-day diagnostic follow-up rise from 90.1% to 93.9%, in a single-institution before-and-after study [1]. Outcome measures show whether a letter change helps.

What is MammoCommunicate?

What it is

MammoCommunicate is the Mammologix service pillar for patient communication support. It creates, delivers, tracks, and documents outreach so follow-up stays visible and moving [1].

How it works

Mammologix tailors patient letter workflows, formats, timing, and structure to each facility's preferences. Touchpoints include lay result letters, reminder letters, overdue follow-up notices, and provider notices. Delivery methods include First Class postage, Certified Mail, patient portal, HL7 transmission, secure fax, and sFTP transfer, with USPS delivery tracking [1].

Why it matters

The practice can see what was sent, when, and by whom, and keeps a documented communication history. That history reduces staff burden and strengthens follow-up review, audit support, and answers to patient questions.

What it means to the patient or the client

Staff spend less time preparing outreach and more time acting on it, because review-ready communication output is prepared for them.

What is the tailored communication story all about?

What it is

A good mammography results letter is tailored at two levels: to the individual patient's understanding, and to the clinical scope and community position of the practice sending it.

How it works

At the patient level, a good letter is accurate, clear, timely, actionable, and compliant [1,4]. AHRQ's Patient Education Materials Assessment Tool (PEMAT) measures whether material is understandable and actionable, which a reading-grade score alone does not show [3]. At the practice level, a screening-only practice and a full diagnostic and surgical center need different messages, and the letter should fit how the practice is established in its community and works with referring doctors and patients [5]. A practice can also use its letters to position or change that standing [5].

Why it matters

At one institution, rewriting a recall letter to about a sixth-grade reading level was followed by a rise in 60-day diagnostic follow-up from 90.1% to 93.9% [2]. That was a single-institution, retrospective before-and-after study, so it does not prove readability alone caused the change [2].

Administration attestation to standard operating policy and procedure

If a letter explains the finding but does not clearly tell the patient exactly what to do next or by when, what would you change first to make the communication clearer without changing the clinical meaning or required regulatory language?

What it is

Mammologix does not set the wording of next steps. It carries out what each client wants, and a client can frame its letters in the way it prefers. Many clients choose general next-step language that tells the patient she has a recommendation and should talk with her healthcare provider, who can walk her through it so she can make an informed decision [1]. The required regulatory language does not change under any option.

How it works

Mammologix explains the reasoning behind the general default, and the client decides. A radiologist makes a recommendation from a short clinical history, usually without seeing the patient. The referring provider knows her full history and continuum of care. If a letter names specific procedures, the patient may carry that list into her appointment, and her provider may decide that only some of them apply. That puts the provider in a difficult position. Recommendations on screening intervals also differ, for example annual versus every two years, among professional organizations and the US Preventive Services Task Force. Under the default, the decision stays with the patient and her provider together [1].

Why it matters

A letter can be clear about what the finding is and still leave the next step to the provider who knows the patient. If a client wants more specific instructions or timeframes, Mammologix can build them into that client's letters.

Administration attestation to standard operating policy and procedure

What can we learn from a near miss where contradictory report language was caught before the patient was notified?

What it is

The lesson is that review before notification is the safeguard. Mammologix reviews each report a minimum of twice. When it finds possible discordance, it holds that patient's notification and asks the client to review.

How it works

Discordance means a recommendation that does not seem to fit the laterality or the imaging assessment. Mammologix has a way to notify the client and request a review before the patient is notified. It suspends the notification process for that patient until the client reports back. Mammologix management reviews the list every day in its management meeting, and each patient on it is reviewed individually every day until a resolution comes back. The patient receives nothing during the hold. The regulation allows 7 days for a suspicious finding and 30 days for a normal finding [1]. Mammologix usually resolves these within 24 to 48 hours, well inside those limits. If the review finds the contradictory language does not affect the notification message to the patient, Mammologix may proceed with the client's permission, without a formal addendum [2].

Why it matters

The patient is never sent a message built on contradictory language, and the hold does not put the notification deadline at risk.

What is the Preventing a Patient Communication Error story about?

What it is

It is a case story on the Mammologix website, titled "The Report That Said Two Different Things," about a report error caught before a patient letter was sent [1].

How it works

A medium-sized breast imaging facility with one interpreting physician had a heavy workload and problems with its dictation system. A report was dictated, transcribed, signed, and released with no alert. About four hours later, a Mammologix team member who was reading the report closely saw that the narrative described a normal screening mammogram with no suspicious findings, while the assessment was Suspicious and recommended an immediate biopsy. The patient letter never went out. Mammologix notified the facility, which issued an addendum, notified the referring physician, traced the discordance to its source, and corrected the record. The patient was not affected [1].

Why it matters

Mammologix reviews every report for internal consistency before any patient communication is generated, and it holds a flagged report until the discrepancy is resolved [1]. The story cites a study of 213,977 speech-recognition radiology reports from 147 radiologists, in which 9.7% of reports contained errors and 1.9% contained material errors that could change the interpretation. For a facility reading 5,000 mammograms a year, the story estimates about 95 such reports annually [1].

Administration attestation to standard operating policy and procedure

What should we document about emotional tone so we can later prove not only that a letter was generated, but that the required communication process was actually completed?

What it is

The documentation that proves the process was completed follows what 21 CFR 900.12 requires. The facility must provide each patient with a written summary of the mammography report in lay terms, within the required timeframes, with the required content, including the federally prescribed breast density wording [1]. Mammologix reads the rule as also calling for a reasonable attempt to deliver the letter. Mammologix provides the mechanism and the record for this process [2].

How it works

The FDA sets the wording for the density statement and sets no criteria for emotional tone, so tone is not part of the required record. Tone can still matter as a best practice. Mammologix has tools for it, including PEMAT and Flesch-Kincaid readability statistics, and works with clients on them. B043 describes those tools [2].

Why it matters

Documentation should show that the mandated steps happened. A record of tone does not show that, and it is a separate question from compliance.

Administration attestation to standard operating policy and procedure

What should we document about reading level so we can later prove not only that a letter was generated, but that the required communication process was actually completed?

What it is

The documentation that proves the process was completed is what 21 CFR 900.12 requires. The facility must provide each patient with a written summary of the mammography report in lay terms, within the required timeframes, with the required content, including the federally prescribed breast density wording [1]. Mammologix reads the rule as also calling for a reasonable attempt to deliver the letter, and Mammologix provides the mechanism and the record for this process [2].

How it works

Reading level is not part of that required record. It is a separate best-practice question, and Mammologix is glad to help with it. Mammologix provides readability statistics, including Flesch-Kincaid and PEMAT, and can help a client model its letters. It can also run A/B testing to see which versions patients adopt better. A client that wants to go further can follow up with patients using its own tools for determining patient preference. B043 describes these tools [2].

Why it matters

Reading level and documented completion answer different questions. Keeping them separate shows that the mandated steps happened, and it still leaves the client free to improve its letters.

Is the 30 day deadline for reports and lay summaries a target, and why is it 7 days for some results?

What it is

The FDA said the 30 day deadline is a maximum and a baseline standard, and that facilities may set shorter deadlines. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

All reports and lay summaries, regardless of the assessment, must be sent within 30 calendar days of the examination. The deadline is tied to the date of the examination, not to the receipt of prior images for comparison, because the receipt of priors can be unpredictable and could delay reporting. For positive mammograms, meaning Suspicious or Highly Suggestive of Malignancy, the facility must send both the report and the lay summary within 7 calendar days of the final interpretation, because those assessments indicate findings that warrant further evaluation. The final rule also made the 7 day deadline apply to the report sent to a self-referred patient.

Why it matters

The 30 day limit is the ceiling for routine results, and the 7 day limit gives urgent results a faster clock that starts at the final interpretation.

What it means to the patient or the client

For patients: a normal result is sent within 30 days, often sooner, and a suspicious result letter should reach you within 7 days of the final interpretation. For the client: treat 30 days as a maximum, set an internal target well under it, and track the 7 day clock separately.

Administration attestation to standard operating policy and procedure

A patient says she never received the result letter, but the mailing system shows it was sent and not returned. What does adequate documentation of communication mean in that situation?

What it is

Under 21 CFR 900.12, the facility is responsible for providing the patient with a written summary in lay terms [1]. Adequate documentation shows that the facility did so and made a reasonable attempt to deliver it. No tracking record can guarantee that a letter reached the patient's hands [2].

How it works

Mammologix keeps a record of the steps in the chain. It receives the results, prints the letter in its own offices, and tracks the mail through its partner Pitney Bowes up to the postal carrier's bag. That tracking does not guarantee delivery, because the last step belongs to the postal service [2]. When a patient reports that she did not receive a letter, the client can print another copy on site right away from the Letter Folder in Logix Drive. The client can also notify Mammologix, which dispatches the letter again immediately. Mammologix is an independent party, so this does not depend on the client's internal systems [2].

Why it matters

When a communication is questioned, each party can say it never received the information. A record that shows each step can help the facility show the process was carried out. Patients also often have portal access to their own results through the electronic medical record and do not log in to see them. That is another reason a documented mailing matters [2].

Administration attestation to standard operating policy and procedure

If our patients may receive results through a portal before the required lay communication arrives by mail, what would you change first to make the communication clearer without changing the clinical meaning or required regulatory language?

What it is

The mailed lay letter does not need to change because of the portal. The two documents serve different readers. The portal usually holds the formal report of test results, which is written for the referring clinician or healthcare provider and shared with the patient through the portal. The lay letter is written for the patient in lay terms [1,2].

How it works

The formal report of test results is designed for communication from one healthcare professional to another. This is the reason the Mammography Quality Standards Act requires a separate written summary for the patient, and it is why Mammologix advocates for mailed, written lay results [1,2]. Mammologix works with each client to include all the requirements, and it offers enhanced capabilities for readability, including PEMAT and Flesch-Kincaid statistics. B043 describes those tools. The client decides how its letters are framed [2].

Why it matters

A patient who sees the formal report in a portal is reading clinical language written for her provider. The lay letter gives her the same result in plain terms, and when follow-up is needed, it tells her what happens next.

Administration attestation to standard operating policy and procedure

What is in the letter folder?

What it is

The letter folder is a section of the secure Mammologix client portal where letter-related documents are stored and exchanged with the client.

How it works

Mammologix gives each client a secure portal with an unlimited number of users authorized by the client, with access on a need-to-know basis under the client's own guidelines. The portal is divided into folders, including a reporting folder and a letter folder. The letter folder holds secure copies of letters, a complete set of sample letters for inspection preparation or reference, and a way to exchange a letter when a client needs one. Clients on the self-service plan, where Mammologix generates the letters and the client prints them on site, retrieve them through the portal.

Why it matters

The client has secure access to its own letters and sample letters without a phone call or an email request. It also resolves the common case where a patient says a letter never arrived.

Why are names and addresses in capital letters on Mammologix patient lay letters?

What it is

Mammologix formats the mailing address block on patient lay letters in uppercase with open punctuation, meaning punctuation is left out. This follows USPS Publication 28, the Postal Addressing Standards, which recommends uppercase, machine-printed addresses with punctuation omitted so automated sorting equipment can read the address block accurately.

How it works

Lay letters mail in volume through #10 window envelopes, so the address block that shows through the window is the part the postal sorting equipment reads. Mammologix prints that block in uppercase and without punctuation, following the readability recommendations in USPS Publication 28. To build the block, Mammologix Policy 1.20 asks the facility to send the patient name split into first and last name fields (middle name optional) and the patient mailing address split into separate fields for street address, city, state, and ZIP code. The window envelope also serves a second purpose in mail production. According to Mailing Systems Technology, the best aspect of window envelopes is the ability to verify the contents after the machine has inserted the material. Printing a small 2D barcode or text in the address block allows cameras mounted at the end of the inserting line to scan through the window and compare document ID numbers against a file of expected mail pieces. If the cameras detect a missing, out of sequence, or duplicate ID number, the inserting machine can stop so operators can diagnose the problem. Closed face (windowless) envelopes do not allow this kind of check through the envelope. The address formatting is separate from the content of the letter itself. Under 21 CFR 900.12(c)(2), every lay summary must, at a minimum, include the name of the patient; the name, address, and telephone number of the facility that performed the mammographic examination; and the required breast density assessment statement. The FDA says MQSA inspectors check patient lay summary letters for the patient's name, the facility address, and the federal breast density notification statement.

Why it matters

MQSA requires that every patient receive a lay summary within 30 calendar days of the mammographic examination, and within 7 calendar days of the final interpretation when the assessment is Suspicious or Highly Suggestive of Malignancy. A letter can only meet its purpose if it reaches the patient. An address block that automated equipment can read accurately supports reliable delivery of letters mailed in volume. Mailing Systems Technology also notes that mail piece integrity checks are more important than ever: once used only for transactional documents, accounting for every mail piece is now necessary on nearly all mailing jobs, and window envelopes give mail operations a level of confidence that closed face envelopes cannot. For patient results letters, that means the visible address block helps confirm that each letter is present and in its envelope. The uppercase format is a USPS readability recommendation, not an MQSA requirement; the MQSA content requirements for the letter apply regardless of how the address block is formatted.

What it means to the patient or the client

For patients: your name and address appear in capital letters with no punctuation because that is the format the Postal Service recommends for machine reading. It is not an error. The address showing through the envelope window is also what lets mail equipment read and account for each letter. For the client: send the patient name and mailing address in the separate fields Mammologix asks for (first name, last name, street address, city, state, and ZIP code) so the address block can be built cleanly for the envelope window.

Administration attestation to standard operating policy and procedure

What should a lay letter say when the facility cannot schedule the recommended procedure itself?

What it is

The letter should say plainly what the facility does and does not do, so the patient is not led to expect a service the facility cannot provide.

How it works

Mammologix comes alongside each client and tailors the letter to what that facility can and cannot do. The letter can name a specific location for the recommended procedure, refer the patient to a different place, or state that the procedure is not performed at the facility and must be done elsewhere. A common case is a screening-only location that sends patients to a more complete diagnostic center within its own organization. Mammologix writes those letters to fit that arrangement [1].

Why it matters

A patient who thinks she can get the next step at the screening location may lose time when she finds out she cannot. A clear letter tells her where to go.

Administration attestation to standard operating policy and procedure

Does MammoCommunicate send density notifications?

What it is

Yes. MammoCommunicate lay letters include breast-density notification language.

How it works

Federal MQSA rules require standardized density wording in the patient lay summary, with separate wording for dense and not dense breasts, based on how the mammography report classifies the patient's breast tissue [1]. These requirements have applied since September 10, 2024 [2]. MammoCommunicate uses the federal wording that matches the density in the report, and it does not rewrite the required statement [1,2]. Some states require additional wording. FDA recommends keeping additional information separate and distinct from the required federal statement, and Mammologix works with each client to include state-required wording that way [2,3].

Why it matters

Every patient receives the federal baseline message, and the facility also meets any state requirement.

What is lay communication assurance?

What it is

Lay communication assurance is Mammologix's term for helping a client assure that its lay results process is completed and fulfilled. "Lay results," or the lay summary, is the FDA's term for the written summary of the mammography report, in lay terms, that each patient must receive [1].

How it works

Under 21 CFR 900.12, a facility must provide each patient with a summary of the mammography report written in lay terms [1]. Mammologix comes alongside the client to help assure that this process, as required under MQSA, is met. Mammologix does not replace the facility's responsibility. It helps assure the process is completed.

Why it matters

The lay summary is a federal requirement, and a facility that does not complete it reliably carries compliance risk. Assurance gives the client a structured way to meet it consistently.

Does a lay summary have to use the word Benign or the report's assessment wording?

What it is

No. The FDA said the explanatory language that follows an assessment category is not part of the assessment statement and is not required in the lay summary, and that even the word Benign need not be stated to the patient. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

The FDA gave examples of lay phrasing for a negative or benign report, such as "Your mammogram is normal" or "Your mammogram shows no sign of cancer," or similar phrasing. The lay summary is a summary in lay terms; the required assessment wording is for the report to the referring provider.

Why it matters

Plain wording is allowed for the patient, so a facility can write the letter at an appropriate reading level without repeating clinical terms.

What it means to the patient or the client

For patients: your letter can say your mammogram is normal in everyday words. For the client: write lay summary templates in plain language, and keep the required density statement and the required facility information in them.

Does a second opinion or an outside reader's report need its own lay summary?

What it is

Yes, in the situations the FDA described when it answered a comment about reinterpretation and contract readers. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

If a previously interpreted mammogram is reinterpreted, the second or later interpreting physician must also meet the personnel requirements in 21 CFR 900.12(a)(1) and must separately comply with the reporting requirements of 900.12(c). To distinguish them from the original, the FDA recommends that a second or later report and lay summary be identified as a second opinion or similar term. If the interpreting physician is a contractor or consultant rather than an employee, that physician must also meet all personnel requirements, and the report and lay summary must meet all reporting requirements.

Why it matters

Each interpretation is a separate report, and the requirements follow the interpretation, not the employment status of the reader.

What it means to the patient or the client

For patients: if your mammogram is read again, the second reading should come with its own report and lay summary, marked as a second opinion. For the client: confirm contract readers meet the qualification rules, and label second opinions clearly.

Does the lay summary have to name the interpreting physician?

What it is

No. The FDA decided not to require the name of the interpreting physician in the lay summary, though a facility may include it. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

The FDA explained that the lay summary is prepared after the examination has been interpreted, so adding the physician's name would not reach the patient early enough for her to ask for a different interpreting physician. A patient who prefers a particular physician would have to ask facility staff before the mammogram is interpreted. After interpretation, the physician's name is in the report to the referring provider, and the patient can request it from the facility or from the referring provider.

Why it matters

The name is available through the report even though the lay summary does not have to carry it.

What it means to the patient or the client

For patients: if you want to know who read your mammogram, ask the facility or your referring provider. For the client: decide as a policy whether to print the physician's name on the lay summary, and have front-desk staff ready for the question.

Must the lay summary and density notification be translated into other languages?

What it is

No. The FDA decided not to add language requirements for the lay summary, and the required breast density statements are in English (21 CFR 900.12(c)(2)(iii) and (iv)). The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

The FDA acknowledged that patients with limited English literacy may need help interpreting the lay summary, but said the MQSA sets baseline national standards and that it is not practical for the agency to regulate translation. Facilities are encouraged to make every effort to communicate with their patients and may choose to provide a translation of the density statement. The English statement must still be included in the lay summary regardless of any additional information or translation the facility provides.

Why it matters

A translation can be added, but it cannot replace the required English statement.

What it means to the patient or the client

For patients: a facility may give you a translated version, but the English statement will still be in your lay summary. For the client: if you offer translations, include the required English wording as well, and have the translation checked for meaning.

What facility information must a lay summary show, and what may a facility add?

What it is

The lay summary must include the name, address, and telephone number of the facility that performed the mammographic examination (21 CFR 900.12(c)(2)). The FDA's responses to comments explain how far that goes. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

Because the FDA identifies each facility by its unique location, the location of the facility where the mammogram was performed must appear in the lay summary, and the facility telephone number must be included. The FDA did not require parent company or network information, because it identifies facilities by location and not by affiliation, but a facility may choose to add information about a healthcare network, an affiliated site, or a records storage site. The FDA also declined to require an email address or instructions for clear communication, because some facilities have no email and some communicate through patient portals, though a facility may include them.

Why it matters

The required elements identify where the examination happened and how to reach that location. Extra contact details are the facility's choice.

What it means to the patient or the client

For patients: your lay summary should tell you where your mammogram was done and give a telephone number for that facility. For the client: use the physical location that performed the exam, and add a records contact or email only if you want to.

Must a facility send a written lay summary when the result is incomplete and more imaging is needed?

What it is

Yes. The FDA's Small Entity Compliance Guide says that even if the result is given to the patient verbally and more imaging is needed, the facility must send a written lay summary within 30 calendar days of the exam, and it should indicate that additional imaging is needed.

How it works

If the follow-up exam results are available within 30 calendar days of the first exam, the facility might combine them into one lay summary, and that combined summary should say it covers both the initial and the follow-up examinations. If the follow-up results are not available within 30 days, the facility must send two lay summaries, one for each exam, each within 30 calendar days of the exam it covers (21 CFR 900.12(c)(2)). Where the assessment is Suspicious or Highly Suggestive of Malignancy, the 7 calendar day deadline applies instead.

Why it matters

A verbal result does not replace the written lay summary, and each exam has its own deadline.

What it means to the patient or the client

For the client: set your letter process so that an incomplete result still generates a lay summary on the first exam's clock, and decide in advance when you will combine and when you will send two letters.

What is the difference between a self-referred patient and a self-requesting patient under MQSA?

What it is

In the FDA's Small Entity Compliance Guide, self-referred patients come for mammography but have no healthcare provider, or decline one, or have a provider who declines responsibility. Self-requesting patients come on their own initiative but can name a healthcare provider, or accept one the facility offers, who takes responsibility for their breast care.

How it works

Self-referred patients must receive the written mammography report as well as the lay summary, so they can give their results to a new provider. The facility must have a system for referring them to a healthcare provider when clinically indicated, including when the assessment is Probably Benign, Suspicious, or Highly Suggestive of Malignancy. Self-requesting patients must receive the same communication of results as referred patients (21 CFR 900.12(c)(2)(i) and (ii)).

Why it matters

The two groups get different reports, so a facility needs to record which one each patient is at registration.

What it means to the patient or the client

For the client: add a registration field that records whether the patient named a provider, and route self-referred patients to both documents and a documented referral step.

If a patient finally schedules after the 60-day letter, do the later letters automatically stop?

What it is

Scheduling does not stop the 30, 60, and 90-day reminder process. Only the patient actually returning for the recommended procedure stops it [1].

How it works

A scheduled appointment is an intention, not a completed follow-up. Patients reschedule, cancel, and fail to appear, so the reminder sequence continues until the patient has the procedure and the follow-up is obtained. Once the patient returns, the loop is closed and the later letters stop [1].

Why it matters

Scheduling is not obtaining the follow-up. Stopping the letters at the scheduling step would leave the patient without a reminder if the appointment falls through, and the recommendation would still be open.

What is the 99 percent reduction in staff time per letter metric?

What it is

The 99 percent reduction in staff time per letter is the reduction in the time a client's staff spends on each letter under the Premier service, compared with producing the letter in house [1].

How it works

Premier is an autonomous service. Mammologix takes on the burden of producing and sending the letters. The client's role is to check in routinely and confirm the work is done as recommended [1].

Why it matters

Staff time goes to patients and procedures instead of letter production, while the client keeps oversight through its routine check-ins.

What samples are in the Letter Folder?

What it is

The Letter Folder is a set of sample letters, one for each scenario a client uses, produced on the client's own letterhead with full body content. The samples are organized and paginated by category so administration, a reviewer, or an inspector can see the letters at a glance [1].

How it works

Here are some of the samples that are included: - Routine follow-up notification - Routine follow-up notification with a recommendation to follow up in less than one year - Early follow-up recommendation notification - Recommendation to obtain a biopsy notification - Recommendation to obtain a surgical consultation notification - Obtain prior images and, if unavailable, obtain additional follow-up notification - Overdue for follow-up notification - Overdue inquiry for physician notification reminder letter (written for the physician, not the patient) - Early follow-up reminder letter - Routine follow-up reminder letter Each scenario except the two reminder letters has a corresponding addendum letter. An addendum letter is a separate required communication under MQSA whenever previous films are reviewed or an addendum is created, even if the assessment is unchanged [1,2]. Scenarios also come in dense, not dense, high-risk, and self-referred variants where the wording differs. All sample data is fictitious [2].

Why it matters

The folder shows exactly what a patient will receive in every situation before a single letter is mailed. This is a sample of some of the scenarios, not the complete list. Mammologix adds client-specific scenarios on request, and the client decides how its letters are framed [2].

Administration attestation to standard operating policy and procedure

You caught a normal-body / biopsy-assessment conflict before a letter went out in one story. How often do you look for that kind of mismatch for clients?

What it is

Mammologix looks for that kind of discordance on every report, every time. Each report is reviewed a minimum of twice [1].

How it works

Mammologix reviews the whole report, not a single field. It looks at the procedure performed, when and where it was performed, and why it was performed. It looks at the key findings, the impression, the recommendation, and the imaging assessment, and checks whether they all flow together and agree with each other. Mammologix notes any possible discordance and brings it to the client's attention before any further action is taken [1].

Why it matters

A report can contain a narrative, an assessment, and a recommendation that do not agree. Reading all of them together, and telling the client before a patient notification goes further, gives the client the chance to resolve the question first. E446 describes what happens next.

Administration attestation to standard operating policy and procedure

A suspicious mammogram report is amended after the seven-day patient notification window has already started. Which version controls the communication deadline and what should be documented?

What it is

The regulation does not address amended or addended reports. 21 CFR 900.12 runs the 7-day deadline for a Suspicious or Highly Suggestive of Malignancy result from the final interpretation of the mammograms, and it runs the 30-day deadline for other results from the date of the examination [1]. Mammologix works on behalf of what is supposed to happen next for the patient, and it always asks the client for clarification when a question comes up [2].

How it works

When an addendum changes the assessment, Mammologix treats the addendum as the new final interpretation and restarts the clock. The provider communication and lay summary obligations under 900.12(c)(2) and (c)(3) then run from that new date [1,2]. When an addendum does not change the assessment, the clock does not restart, and Mammologix reviews the recommendation and handles the work as it normally would. Either way, an addendum always results in a letter to the patient. If the assessment and recommendation are unchanged, the letter says that more information has been made available to her doctor and restates the current recommendation, such as a biopsy, as that client's letters word it [2]. Documentation: Keep the addendum together with the original report. Have the addendum restate the assessment in one line, such as "Final assessment unchanged: Negative." Record the original interpretation date, the addendum date, the prior assessment, and any new assessment [2].

Why it matters

An addendum circulated without an assessment, or without the original report, can be read as a report missing a required element. Clear records remove that question.

Administration attestation to standard operating policy and procedure

An addendum reversed a biopsy recommendation after the lay letter mailed. What retraction workflow exists?

What it is

Mammologix does not retract the first letter. The original letter was correct when it went out, and the addendum triggers a new notification.

How it works

This answer assumes the original recommendation came from a final report signed by the interpreting physician and released to both the physician and the patient's medical record. It does not cover a report released by mistake. Under 21 CFR 900.12, the patient must be notified of the result, and here she was [1]. When the addendum reaches Mammologix, it goes through the same process as every other report. Mammologix reads the report for the reason for the exam, what the report says, what is recommended, and the assessment. It then sends the notification that matches the new information [2]. If a biopsy recommendation changes to a 6-month follow-up, the patient is told that additional information is now available, that follow-up is now recommended, and to talk with her doctor.

Why it matters

The patient always learns what happens next. Mammologix keeps tailored messages for addenda as well as for first assessments.

Administration attestation to standard operating policy and procedure

What is the handoff phone number and email?

What it is

The answer depends on which handoff is meant. It could be the contact number a facility prints on its own lay letters, the way to reach Mammologix, or a handoff point set out in a client's contract.

How it works

For a facility's lay letters, the facility chooses the contact. Under 21 CFR 900.12, the lay summary must include the facility's name, address, and telephone number, so the patient has a way to reach the facility [1]. The regulation does not require an email address [1]. To reach Mammologix, call 1-800-739-6919, which is answered by a live person 24 hours a day, 7 days a week, or write to connect@mammologix.com, which is read by a live person and is not routed automatically [2]. Where a client has a contractual question about who hands off to whom, the client's own agreement with Mammologix governs.

Why it matters

A patient needs a working number on the letter to reach the facility. A client needs a dependable way to reach Mammologix.

Administration attestation to standard operating policy and procedure

What is the Letter Folder in Logix Drive?

What it is

Logix Drive is the name of the secure Mammologix client portal. The Letter Folder is the part of Logix Drive where a client's letter-related documents are kept [1].

How it works

Each client has access to Logix Drive, with an unlimited number of users authorized by the client and access limited to need to know. Logix Drive is divided into folders, including a reporting folder and the Letter Folder. The Letter Folder holds secure copies of patient letters and a complete set of sample letters for inspection preparation or reference. Clients on the self-service plan, where Mammologix generates the letters and the client prints them on site, retrieve those letters from the Letter Folder [1].

Why it matters

The client can reach its own letters at any time without a phone call or an email request. It also gives staff a quick way to answer a patient who says a letter never arrived.

Administration attestation to standard operating policy and procedure

Where does a recommendation letter pull its next-step sentence when contrast-enhanced mammography (CEM) is added as a problem-solving exam after ultrasound?

What it is

Adding CEM does not need a separate pathway. The next-step sentence comes from the same client-specific, tailored letter logic used for every other recommendation.

How it works

Clients set different recommendations by different criteria, such as age and breast density. One client may want ultrasound only at certain ages. Another may send patients to MRI instead of CEM after ultrasound, depending on density. Mammologix builds those protocols into switches in the letters, or follows the client's standing orders. Mammologix also reads every report at least twice and checks it against what is supposed to happen next for the patient, so the letter matches the recommendation, and exceptions are caught [1].

Why it matters

A new exam such as CEM only needs the client's rules for when to use it. The patient's letter then states the next step that client actually recommends.

Administration attestation to standard operating policy and procedure

Does MammoCommunicate support multilingual letters?

What it is

Yes. Mammologix provides multilingual letters and works with each client on them.

How it works

The client tells Mammologix which language and which dialect it wants. A language such as Spanish has different dialects, so both need to be specified. Mammologix policy is to always send the English letter. The patient also receives a second letter in the requested language. Every patient who gets a multilingual letter therefore gets two letters, and the second letter complements the English one and never replaces it [1].

Why it matters

The patient receives the letter in a language she can read, and the facility always has the English letter on record. Mammologix has found that this arrangement works best.

What is the "code in, letter out" model that Mammologix criticizes?

What it is

"Code in, letter out" is a system design that takes the BI-RADS assessment category from a mammography report and immediately maps it to one fixed patient letter [2]. A BI-RADS 3 always gets one letter, and a BI-RADS 1 always gets another [2].

How it works

The model assumes the assessment category fully determines what the patient should be told [2]. In practice, an assessment and a recommendation do not always coincide [2]. A BI-RADS 1 or 2 result can carry a recommendation to see a surgeon, for example because of a palpable or dermal finding, and a BI-RADS 3 result can carry a recommendation other than short-interval follow-up [2]. This discordance can occur at any assessment level [2].

Why it matters

A letter chosen from the code alone can tell the patient something different from what the interpreting physician recommended. In a study of community breast MRI examinations, 64% (535 of 837) of BI-RADS category 3 assessments had a discordant recommendation [1].

What it means to the patient or the client

The patient may receive instructions that do not match the recommendation, and the practice carries the risk of that gap.

Where does MQSA set a hard requirement for returned mail, and where does a facility still have room to improve readability, tone, layout, or actionability?

What it is

The hard requirement is the federal rule in 21 CFR 900.12: the facility must provide each patient with a lay summary within the required timeframes [1]. Mammologix's reading is that the key requirement is a reasonable effort to send the letter. How the letter reads, looks, and prompts action is where the facility has room to improve.

How it works

A mailed letter can come back undeliverable, so a facility needs an organized way to process returned letters and then make a reasonable attempt to reach the patient another way [2]. The text of the regulation does not set standards for tone, layout, or actionability. Facilities can work on those themselves. For the tools and tests Mammologix provides for readability, comprehension, and A/B testing, see B043.

Why it matters

A letter that was sent but never received does not help the patient. A documented returned-mail process shows the facility made a reasonable effort.

What do the two breast density statements in the lay summary say?

What it is

The lay summary must contain one of two statements about breast density, chosen by the density category in the mammography report (21 CFR 900.12(c)(2)(iii) and (iv)).

How it works

If the report says the breasts are almost entirely fatty, or that there are scattered areas of fibroglandular density, the summary includes the statement that breast tissue can be dense or not dense, that dense tissue makes cancer harder to find on a mammogram and raises the risk of developing breast cancer, and that the patient's breast tissue is not dense. If the report says heterogeneously dense or extremely dense, the statement says the patient's tissue is dense, adds that other imaging tests in addition to a mammogram may help find cancers in some people with dense tissue, and tells the patient to talk with a healthcare provider. Both end by advising the patient to talk to a healthcare provider about density, risks, and the individual situation.

Why it matters

Four report categories lead to two patient statements. The regulation prescribes the statements, so the safe practice is to insert them exactly as written for each category.

What it means to the patient or the client

For patients: the letter tells you in plain words whether your breast tissue is dense, and that you can talk with your healthcare provider about it. For the practice: the statement depends on the density category in the report, so a template that links the two prevents the wrong statement going out.

What must a patient lay summary letter include at a minimum?

What it is

21 CFR 900.12(c)(2) sets the minimum content of the lay summary a facility gives each patient.

How it works

At a minimum the summary includes the patient's name, the name, address, and telephone number of the facility that performed the examination, and an assessment of breast density using the statements set out in 21 CFR 900.12(c)(2)(iii) and (iv). It must be written in lay terms.

Why it matters

Missing one of these elements is an easy finding at inspection. A template that fills the facility's name, address, and telephone number and inserts the correct density statement each time keeps every letter compliant.

What it means to the patient or the client

For patients: the letter shows your name and the name, address, and telephone number of the facility, so you know whom to call with questions. For the practice: an inspector can check these elements quickly, so build them into the template once.

When must a facility send the patient lay summary of the mammography result?

What it is

Each facility must give every patient a summary of the mammography report written in lay terms (21 CFR 900.12(c)(2)).

How it works

The summary is due within 30 calendar days of the mammographic examination. If the assessment is Suspicious or Highly Suggestive of Malignancy, it is due within 7 calendar days of the final interpretation of the mammograms. A patient who names no healthcare provider also receives the full mammography report, on the same timing.

Why it matters

The two clocks start at different points: 30 days from the examination, and 7 days from the final interpretation. Letter workflows that track both dates avoid late letters for the cases that matter most.

What it means to the patient or the client

For patients: you should receive a plain language summary within 30 days of your exam, and within 7 days of the final interpretation if the result is Suspicious or Highly Suggestive of Malignancy. For the practice: track the two clocks separately so the urgent letters never wait on the 30 day schedule.

Can a patient ask to receive health information by a different address or method?

What it is

Yes. Under the HIPAA Privacy Rule, a covered health care provider must permit individuals to request, and must accommodate reasonable requests, to receive communications of protected health information by alternative means or at alternative locations (45 CFR 164.522(b)).

How it works

The provider may require the request in writing, and may condition the accommodation on information about how payment will be handled and on the individual giving an alternative address or other method of contact. The provider may not require an explanation of why the individual is asking.

Why it matters

A reminder or result letter that goes to the usual address can reach someone the patient did not want to see it, so the rule gives patients a way to choose.

What it means to the patient or the client

For patients: you can ask the facility to send your results and reminders to another address or by another method. For the client: have a written request process and record each patient's preference where the staff and any letter vendor can see it.

Is an incidental disclosure during a permitted communication a HIPAA violation?

What it is

Not by itself. The Privacy Rule permits a use or disclosure that is incident to a use or disclosure otherwise permitted, provided the covered entity has complied with the applicable minimum necessary requirements and the safeguards standard (45 CFR 164.502(a)(1)(iii)).

How it works

The condition is compliance: the entity must have applied the minimum necessary rule where it applies and reasonable safeguards under 164.530(c). If those were not in place, the protection for the incidental disclosure does not apply.

Why it matters

The permission is conditional, so it depends on the facility's own safeguards being real and documented.

What it means to the patient or the client

For the client: limit what a reminder, envelope, or voicemail shows to what is needed, and keep your safeguards documented so you can show you complied if a question arises.

What safeguards does HIPAA require when a facility communicates with patients?

What it is

A covered entity must have in place appropriate administrative, technical, and physical safeguards to protect the privacy of protected health information (45 CFR 164.530(c)).

How it works

The entity must reasonably safeguard protected health information from any intentional or unintentional use or disclosure that violates the Privacy Rule, and must reasonably safeguard it to limit incidental uses or disclosures that happen as part of an otherwise permitted use or disclosure. The rule states the standard; it does not list particular channels such as mail, email, text, or portals, so the facility decides what is reasonable for each.

Why it matters

Because the standard is reasonableness, a facility needs a documented judgment for each channel it uses, not a single blanket rule.

What it means to the patient or the client

For the client: write down which channels you use for reminders and results, what each can show, and what safeguards apply, and keep that with your privacy policies.

When must the mammography report reach the referring provider?

What it is

When a patient has a referring healthcare provider, or names one, the facility must send that provider the written mammography report (21 CFR 900.12(c)(3)).

How it works

The report, with the items listed for mammography reports, is due as soon as possible and no later than 30 days from the date of the examination. If the assessment is Suspicious or Highly Suggestive of Malignancy, the report is due within 7 calendar days of the final interpretation, to the referring provider or, if unavailable, to a responsible designee of that provider.

Why it matters

The designee provision matters when the referring provider is away. Naming a backup recipient in the referral record helps meet the 7 day deadline.

What it means to the patient or the client

For patients: your provider receives the written report within 30 days, or within 7 days of the final interpretation for a suspicious or highly suggestive result, so your next step can be planned. For the practice: record a backup recipient for each referring provider so the 7 day deadline can be met when the provider is away.

Administration attestation to standard operating policy and procedure

What response rate did the personal re-engagement letter produce?

What it is

Mammologix provides services to re-engage patients who have not returned, at different levels based on each client's requirements, recommendations, and input. Response rates have been as high as 25% [1].

How it works

The rate varies with several factors, including the timing, the wording, and the framing of the letter. These are individual facility criteria that Mammologix designs together with each client. Mammologix is glad to offer its input, its data, and its recommendations, and the client always has the final say [1].

Why it matters

The 25% figure is the high end of what Mammologix has seen, and it can differ from one client and one letter to another. It reflects what a design the client has chosen can produce, and it should not be read as a result Mammologix can promise.

Is there evidence that reminders increase mammography screening?

What it is

Yes, reminders are one of several approaches with published support. A 2025 systematic review and meta-analysis of 44 randomized studies with 161,141 people found that interventions to increase breast cancer screening raised mammography uptake compared with usual care (pooled odds ratio 1.55, 95% CI 1.39 to 1.73).

How it works

The authors report that educational interventions were the most effective overall. Among underserved groups, they report that reminders, telephone outreach, navigation services, and culturally sensitive approaches were highly effective (pooled odds ratio 1.81, 95% CI 1.43 to 2.28, across interventions for those groups). A 2023 systematic review of low and middle income countries, based on only five studies, listed client reminders among strategies that can raise use of mammography and found multicomponent interventions more effective than single ones.

Why it matters

These reviews measure whether women are screened, not whether they return within a set number of months, and they do not say how often to send a reminder or whether a mailed reminder adds to a portal message. Those choices rest on a facility's own data.

What it means to the patient or the client

For the client: use reminders as part of a combination of outreach steps, and track your own return rates by channel to learn what works for your patients.

Where does a navigator find the NCCN language on supplemental screening for dense breasts versus what a lay letter is allowed to say?

What it is

A navigator can find the current NCCN language on the NCCN website (nccn.org). The NCCN language is background knowledge. What the lay letter must say is set by the federal rule, and the navigator can add to it.

How it works

The required federal breast-density notification is set by the FDA, with separate wording for dense and not dense breasts [1]. FDA recommends that any additional information stay separate and distinct from that required statement [1]. A navigation team can add supplemental information that fits the patient and the facility. A younger patient with dense breasts may be routed to ultrasound, which uses no radiation. Another may be routed to contrast-enhanced mammography, which does use radiation, and another to breast MRI. The choice depends on the patient and the facility's protocols [2]. Mammologix works with each client to frame these supplements and build the scaffolding for those letters [2].

Why it matters

The letter meets the regulatory requirement, and it also meets the needs of the facility and the navigation team, so the patient gets the next step in her care.

NCCN patient guidelines and NCCN physician guidelines differ in tone. Which, if either, informs letter inserts?

What it is

Neither NCCN version is the governing source for a patient lay letter. The federal MQSA regulation, 21 CFR 900.12, is the standard Mammologix always references for lay summaries [1].

How it works

NCCN publishes both professional and patient-facing material, but the lay summary requirement comes from the FDA regulation [1]. States set their own additional requirements, separate from MQSA. For example, Maryland and North Carolina each require specific wording that Mammologix builds into letters [3]. Through MammoCommunicate, Mammologix works with the client to meet the federal and state requirements and to make sure the patient understands the letter, using the Patient Education Materials Assessment Tool (PEMAT) to check understandability and actionability [2].

Why it matters

A letter can satisfy every required element and still leave the patient unsure what to do. Mammologix aims for both: meeting the requirements and a patient who can take the next step.